11 completed, 1 terminated, 1 unknown. 13 Phase 3.
By phase and status
Follow Antirheumatic Agents: new trials by email Literature Review of Antirheumatic Agents trials Research Report on Antirheumatic Agents
Trials (filtered) newest first · largest first
All 13 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Effectiveness of Probiotics in Patients of Mild to Moderate Rheumatoid Arthritis
probiotic plus standard treatment, standard treatment - Rheumatoid Arthritis | Phase 3 | Completed | 88 | 2023-08-24 | 2024-09-19 |
A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)
Peficitinib, Plaebo, Disease-modifying antirheumatic drugs (DMARDs) - Rheumatoid Arthritis (RA) | Phase 3 | Completed | 385 | 2018-09-27 | 2024-10-21 |
A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent
Tocilizumab, DMARDs, Oral Corticosteroids - Rheumatoid Arthritis | Phase 3 | Completed | 162 | 2014-03-04 | 2018-12-07 |
A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants
Tocilizumab, DMARDs - Rheumatoid Arthritis | Phase 3 | Completed | 227 | 2013-09-05 | 2017-07-11 |
A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis
DMARD, methotrexate, tocilizumab [RoActemra/Actemra] - Rheumatoid Arthritis | Phase 3 | Completed | 401 | 2013-09-01 | 2018-01-26 |
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With DMARDs Versus DMARDs Alone in Patients With Rheumatoid Arthritis
DMARDs - Combination With DMARDs | Phase 3 | Unknown | 98 | 2013-09-01 | 2018-04-17 |
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis
tocilizumab SC, tocilizumab IV, placebo to tocilizumab SC - Rheumatoid Arthritis | Phase 3 | Completed | 1262 | 2010-09-01 | 2016-06-20 |
To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis
Tocilizumab, DMARDs - Rheumatoid Arthritis | Phase 3 | Completed | 89 | 2010-03-01 | 2013-11-20 |
Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX
CP-690,550, Disease-modifying antirheumatic drug - Arthritis, Rheumatoid | Phase 3 | Completed | 956 | 2010-01-01 | 2018-04-06 |
Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis
tocilizumab, DMARDs, Placebo - Rheumatoid Arthritis | Phase 3 | Completed | 90 | 2009-10-01 | 2010-11-03 |
A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs
DMARDs, Tocilizumab - Rheumatoid Arthritis | Phase 3 | Completed | 58 | 2009-10-01 | 2017-06-19 |
Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)
infliximab, DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89. - Rheumatoid Arthritis | Phase 3 | Terminated | 8 | 2007-06-01 | 2017-04-12 |
An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies
Tocilizumab, Disease-modifying anti-rheumatic drugs, Non-steroidal anti-inflammatory drugs - Rheumatoid Arthritis | Phase 3 | Completed | 2067 | 2005-09-01 | 2014-09-30 |
Conditions studied
Arthritis, Rheumatoid (12) · Autoimmune Diseases (1) · Joint Diseases (1) · Rheumatic Diseases (1)
Sponsors
Hoffmann-La Roche (6) · JW Pharmaceutical (2) · Astellas Pharma China, Inc. (1) · King Edward Medical University (1) · Merck Sharp & Dohme LLC (1) · Mycenax Biotech Inc. (1) · Pfizer (1)
Countries
Italy (4) · South Korea (4) · Spain (4) · Argentina (3) · Australia (3) · Brazil (3) · Canada (3) · Germany (3) · Mexico (3) · Peru (3) · Puerto Rico (3) · Russia (3) · Taiwan (3) · Thailand (3) · United Kingdom (3)
Top investigators
Gulraiz Iqbal, MBBS (1) · Hsiao-Yi Lin, PHD (1)
Results publications
PMID 29244149, PMID 30649524, PMID 32508063, PMID 24941177, PMID 25047021, PMID 26056119, PMID 27175296, PMID 27493790, PMID 27909081, PMID 28143815, PMID 29696833, PMID 29761420, PMID 30177460, PMID 31087542, PMID 31431998, PMID 32816215, PMID 33057725, PMID 33059710, PMID 33127856, PMID 34057820, PMID 34870800, PMID 35577477, PMID 36526796, PMID 36600185, PMID 36601090, PMID 36814062, PMID 36931693, PMID 37453736, PMID 37773189, PMID 38357391, PMID 38883150, PMID 38958913, PMID 39192350
NIH funding
2009 (2), 2005 (1)